Germany Generic Pharmaceuticals Market

ID: MRFR/MED/43790-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
Germany Generic Pharmaceuticals Market Research Report: Size, Share, Trend Analysis By Types (Simple Generics, Specialty Generics, Biosimilars), By Applications (Central Nervous System Disorders, Respiratory Diseases, Hormones Related Diseases, Gastrointestinal Diseases, Cardiovascular Diseases, Infectious Diseases, Cancer, Diabetes, Others), By Product (Small Molecule, Large Molecule), By Route of Administration (Oral, Injectable, Inhalable, Others) and By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035
Germany Generic Pharmaceuticals Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.72%
2024 Market Size$ 21.89 Billion
2025 Market Size$ 23.59 Billion
2035 Market Size$ 49.62 Billion
Key Players
Teva Pharmaceutical Industries
Sandoz
Mylan
Amgen
Sun Pharmaceutical Industries
Aurobindo Pharma
Trends
  • Rising Demand for Cost-Effective Medications
  • Technological Advancements in Drug Development
  • Regulatory Support for Generic Products
Opportunities
  • Aging Population
  • Rising Chronic Diseases
  • Increasing Healthcare Costs
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Type (USD Billion)
      1. 4.1.1 Small Molecule Drugs
      2. 4.1.2 Biologics
      3. 4.1.3 Biosimilars
    2. 4.2 Pharmaceutical, BY Formulation Type (USD Billion)
      1. 4.2.1 Tablets
      2. 4.2.2 Injectables
      3. 4.2.3 Topicals
      4. 4.2.4 Capsules
      5. 4.2.5 Solutions
    3. 4.3 Pharmaceutical, BY Therapeutic Area (USD Billion)
      1. 4.3.1 Cardiovascular Diseases
      2. 4.3.2 Diabetes
      3. 4.3.3 Cancer
      4. 4.3.4 CNS Disorders
      5. 4.3.5 Infectious Diseases
    4. 4.4 Pharmaceutical, BY Distribution Channel (USD Billion)
      1. 4.4.1 Retail Pharmacy
      2. 4.4.2 Hospital Pharmacy
      3. 4.4.3 Online Pharmacy
      4. 4.4.4 Wholesalers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Teva Pharmaceutical Industries (IL)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sandoz (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Mylan (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Amgen (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sun Pharmaceutical Industries (IN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Aurobindo Pharma (IN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Cipla (IN)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Lupin (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Hikma Pharmaceuticals (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
      10. 5.2.10 Dr. Reddy's Laboratories (IN)
        1. 5.2.10.1 Financial Overview
        2. 5.2.10.2 Products Offered
        3. 5.2.10.3 Key Developments
        4. 5.2.10.4 SWOT Analysis
        5. 5.2.10.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GERMANY MARKET ANALYSIS BY TYPE
    3. 6.3 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
    4. 6.4 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
    5. 6.5 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 PHARMACEUTICAL, BY FORMULATION TYPE, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
    16. 6.16 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    18. 6.18 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
      3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Germany Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Billion, 2025-2035)

  • Small Molecule Drugs
  • Biologics
  • Biosimilars

Pharmaceutical By Formulation Type (USD Billion, 2025-2035)

  • Tablets
  • Injectables
  • Topicals
  • Capsules
  • Solutions

Pharmaceutical By Therapeutic Area (USD Billion, 2025-2035)

  • Cardiovascular Diseases
  • Diabetes
  • Cancer
  • CNS Disorders
  • Infectious Diseases

Pharmaceutical By Distribution Channel (USD Billion, 2025-2035)

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
  • Wholesalers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.